Atractylenolide III Ameliorates Bile Duct Ligation-Induced Liver Fibrosis by Inhibiting the PI3K/AKT Pathway and Regulating Glutamine Metabolism

Atractylenolide III Ameliorates Bile Duct Ligation-Induced Liver Fibrosis by Inhibiting the PI3K/AKT Pathway and Regulating Glutamine Metabolism

Liver fibrosis is one of the leading causes of hepatic sclerosis and hepatocellular carcinoma worldwide. However, the complex pathophysiological mechanisms of liver fibrosis are unknown, and no specific drugs are available to treat liver fibrosis. Atractylenolide III (ATL III) is a natural compound...

Full description

Bibliographic Details
Main Authors: Yan Wang, Kun Shi, Jiyuan Tu, Chang Ke, Niping Chen, Bo Wang, Yanju Liu, Zhongshi Zhou
Format: Article
Language:English
Published: MDPI AG 2023-07-01
Series:Molecules
Subjects:
Atractylenolide III
bile duct ligation
liver fibrosis
PI3K/AKT
glutaminase
Online Access:https://www.mdpi.com/1420-3049/28/14/5504

Internet

https://www.mdpi.com/1420-3049/28/14/5504

Similar Items